Bladder Cancer
Conditions
Keywords
muscle-invasive
Brief summary
The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive bladder cancer (MIBC).
Detailed description
Primary Objective To estimate the proportion of patients with pathological downstaging to \<pT2 after neoadjuvant therapy with pembrolizumab in combination with gemcitabine and cisplatin in patients with MIBC Hypothesis: The rate of pathologic downstaging to \<pT2 will improve compared to historical controls Secondary Objectives To estimate the proportion of patients with pT0 after neoadjuvant therapy with pembrolizumab when administered in combination with gemcitabine and cisplatin in patients with MIBC Hypothesis: The rate of pathologic downstaging to pT0 will improve compared to historical controls To estimate event free survival (EFS) Hypothesis: EFS will be improved compared to historical controls To estimate overall survival (OS) Hypothesis: OS will be improved compared to historical controls To estimate the proportion of patients who are alive at 3 years (OS at 3 years) Hypothesis: OS at 3 years will be improved compared to historical controls To characterize the toxicity profile for the combination of pembrolizumab, gemcitabine, and cisplatin Hypothesis: Pembrolizumab, gemcitabine, and cisplatin will be a safe combination with acceptable toxicity rates Exploratory Objectives To explore the association of biological markers including PD-L1 expression and immune gene expression signatures with pathological downstaging to \<pT2, pT0, EFS, and OS To explore associations between BASE47 "basal," "claudin-low," and "luminal" subtypes of MIBC and pathological downstaging to \<pT2, pT0, EFS, and OS To characterize the change in phenotype of TILs, including delineation of effector and regulatory T cells, before and after neoadjuvant treatment To define T cell receptor (TCR) and B cell receptor (BCR) repertoire profiles that are associated with pathological downstaging to \<pT2, pT0, EFS, and OS First the participant will receive all 3 study drugs (Pembrolizumab/Keytruda, gemcitabine and cisplatin) on the first day of a 3 week "cycle". The participant will then receive cisplatin and gemcitabine on the 8th day of the cycle. The participant will receive the study drugs for 4 cycles for a total of 12 weeks. Participants are followed for 5 years.
Interventions
DRUGpembrolizumab, gemcitabine and cisplatin
neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
Sponsors
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
open label
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Be able to give written IRB approved informed consent and be able to follow protocol requirements. * Be greater than or equal to 18 years of age on day of signing informed consent. * Has a performance status of 0 or 1 on the ECOG Performance Scale * Has histologically confirmed urothelial carcinoma of the bladder; those with mixed histology, including a component of urothelial carcinoma, are eligible. Pure small cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are excluded. * Has clinical stage T2-T4a N0/X M0 urothelial carcinoma. Clinical T stage is based on the pre-study standard of care transurethral resection of the bladder tumor (TURBT) sample and imaging studies. * Has staging scans with abdominal/pelvic CT or MRI scan and CT scan or x-ray of the chest within 4 weeks prior to treatment initiation * Be a medically appropriate candidate for radical cystectomy as determined by an attending urologist and be planning to receive cystectomy. * Has had no prior systemic cytotoxic chemotherapy for urothelial carcinoma (prior intravesicular chemotherapies are permitted) * Patients must have tumor tissue from transurethral resection of the bladder tumor (TURBT) available for submission that is sufficient for correlative testing, and agree to submission of a paraffin block or 20 formalin-fixed paraffin embedded (FFPE) slides of 5-10 microns in thickness. Patients must also agree to submission of tissue from cystectomy. * Demonstrate adequate organ function as defined in the table below; all screening labs should be performed within 10 days of treatment initiation. Hematological Absolute neutrophil count (ANC) ≥1,500 /mcL Platelets ≥100,000 / mcL Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment) Renal Serum creatinine OR Measured or calculated creatinine clearance (CrCL; GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels \> 1.5 X institutional ULN (Creatinine clearance should be calculated per CKD-EPI equation.) Hepatic Serum total bilirubin ≤ 1.5 X ULN (≤ 3 X ULN if Gilbert's Syndrome) OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy. If subject receiving anticoagulants, PT or PTT should be within therapeutic range of intended use of anticoagulants * Female subjects of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of pembrolizumab. * Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year. The two birth control methods can be composed of: two barrier methods or a barrier method plus a hormonal method to prevent pregnancy. Subjects should start using birth control from the screening visit and continue throughout the study period up to 120 days after the last dose of study therapy. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), copper intrauterine device, sponge, or spermicide. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents). * Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy. * Life expectancy greater than 3 months * Consents to whole blood collection prior to initiating therapy and at cystectomy for support of correlative research studies
Exclusion criteria
The subject must be excluded from participating in the trial if the subject meets any of the following: * Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of pembrolizumab. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. NOTE: see exception to use of systemic steroid as prophylactic anti-emetic prior to cisplatin in section 4.2.2. Inhaled and topical steroids are allowed. * Has a known history of active TB (Bacillus Tuberculosis) * Hypersensitivity to pembrolizumab or any of its excipients. * Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. * Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has evidence of interstitial lung disease or active, non-infectious pneumonitis. * Has an active infection requiring systemic therapy * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. * Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) * Has received prior radiation therapy to the bladder for the purpose of treating urothelial carcinoma * Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) * Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). * Has clinically relevant hearing impairment \> Grade 2 * Has received a live vaccine within 30 days prior to the first dose of trial treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy | 14 weeks of treatment plus cystectomy within 70 days after treatment | Pathologic (p) anatomic stage for bladder cancer uses the American Joint Committee on Cancer (AJCC) Tumor/Nodes/Metastasis (TNM) system, which is based on: Size of primary tumor (T) and whether it has grown into nearby areas. Spread to regional lymph nodes (N). Spread (metastasis; M) to other organs of the body. Once the T, N, and M categories have been determined, this information is combined into a prognostic group. Higher numbers mean the cancer is more advanced. Pathologic staging is based on the operative and pathology report from cystectomy at the local site. A pathologic response or downstaging is defined as a reduction in stage to below pathological tumor stage 2 (\<pT2) (pT0-T1N0M0) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects That Reach Complete Pathologic Response (pT0) at the Time of Cystectomy | 14 weeks of treatment plus cystectomy within 70 days of treatment | Pathologic (p) anatomic response for bladder cancer uses the American Joint Committee on Cancer (AJCC) TNM staging system, which is based on: Size of primary tumor (T) and whether it has grown into nearby areas. Spread to regional lymph nodes (N). Spread (metastasis) (M) to other organs of the body. Once the T, N, and M categories have been determined, this information is combined into a prognostic group. Higher numbers mean the cancer is more advanced. Pathologic staging is based on the operative and pathology report from cystectomy at the local site. Complete pathologic response (pT0) is defined as pT0 N0 M0. |
| Event Free Survival | 14 weeks of treatment plus 5 years of followup | defined from D1 of neoadjuvant treatment until progression (in those who progress prior to surgery) or until recurrence (post-surgery) or until death as a result of any cause. |
| Overall Survival (OS) | 14 weeks of treatment plus 3 years or until death | OS at 3 years is defined from D1 of treatment until 3 years or death as a result of any cause |
| Number of Participants With Treatment Related Adverse Events. | 14 weeks of treatment plus 30 days for toxicity followup | Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0, a descriptive terminology. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMatthew I Milowsky, MD
UNC Lineberger Comprehensive Cancer Center
Participant flow
Recruitment details
Subjects were recruited from two cancer centers between May 2016 and March 2020.
Pre-assignment details
Of the 47 participants screened, 8 were determined to be ineligible and a total of 39 were enrolled.
Participants by arm
| Arm | Count |
|---|---|
| Pembrolizumab, Gemcitabine and Cisplatin There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
pembrolizumab, gemcitabine and cisplatin: neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy | 39 |
| Total | 39 |
Baseline characteristics
| Characteristic | Pembrolizumab, Gemcitabine and Cisplatin |
|---|---|
| Age, Continuous | 66 years |
| Clinical Tumor (T) stage T2 | 28 Participants |
| Clinical Tumor (T) stage T3 | 9 Participants |
| Clinical Tumor (T) stage T4a | 2 Participants |
| Eastern Cooperative Oncology Group performance status (ECOG PS) 0 | 28 Participants |
| Eastern Cooperative Oncology Group performance status (ECOG PS) 1 | 11 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 39 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Histology Pure urothelial | 28 Participants |
| Histology Urothelial with glandular and squamous | 1 Participants |
| Histology Urothelial with micropapillary | 1 Participants |
| Histology Urothelial with sarcomatoid | 1 Participants |
| Histology Urothelial with signet ring | 1 Participants |
| Histology Urothelial with squamous cell | 7 Participants |
| Previous Bacillus Calmette-Guérin Therapy No | 34 Participants |
| Previous Bacillus Calmette-Guérin Therapy Yes | 5 Participants |
| Previous non-muscle invasive bladder cancer No | 31 Participants |
| Previous non-muscle invasive bladder cancer Unknown | 1 Participants |
| Previous non-muscle invasive bladder cancer Yes | 7 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 38 Participants |
| Region of Enrollment United States | 39 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 32 Participants |
| Smoking status Current smoker | 7 Participants |
| Smoking status Former smoker | 26 Participants |
| Smoking status Never smoker | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 9 / 39 |
| other Total, other adverse events | 38 / 39 |
| serious Total, serious adverse events | 23 / 39 |
Outcome results
Primary
Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy
Pathologic (p) anatomic stage for bladder cancer uses the American Joint Committee on Cancer (AJCC) Tumor/Nodes/Metastasis (TNM) system, which is based on: Size of primary tumor (T) and whether it has grown into nearby areas. Spread to regional lymph nodes (N). Spread (metastasis; M) to other organs of the body. Once the T, N, and M categories have been determined, this information is combined into a prognostic group. Higher numbers mean the cancer is more advanced. Pathologic staging is based on the operative and pathology report from cystectomy at the local site. A pathologic response or downstaging is defined as a reduction in stage to below pathological tumor stage 2 (\<pT2) (pT0-T1N0M0)
Time frame: 14 weeks of treatment plus cystectomy within 70 days after treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pembrolizumab, Gemcitabine and Cisplatin | Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy | 56 percentage of patients with response |
Secondary
Event Free Survival
defined from D1 of neoadjuvant treatment until progression (in those who progress prior to surgery) or until recurrence (post-surgery) or until death as a result of any cause.
Time frame: 14 weeks of treatment plus 5 years of followup
Secondary
Number of Participants With Treatment Related Adverse Events.
Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0, a descriptive terminology. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.
Time frame: 14 weeks of treatment plus 30 days for toxicity followup
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Pembrolizumab, Gemcitabine and Cisplatin | Number of Participants With Treatment Related Adverse Events. | Grade 1 or higher (Any toxicity) | 39 Participants |
| Pembrolizumab, Gemcitabine and Cisplatin | Number of Participants With Treatment Related Adverse Events. | Grade 3 or higher | 29 Participants |
Secondary
Overall Survival (OS)
OS at 3 years is defined from D1 of treatment until 3 years or death as a result of any cause
Time frame: 14 weeks of treatment plus 3 years or until death
Secondary
Percentage of Subjects That Reach Complete Pathologic Response (pT0) at the Time of Cystectomy
Pathologic (p) anatomic response for bladder cancer uses the American Joint Committee on Cancer (AJCC) TNM staging system, which is based on: Size of primary tumor (T) and whether it has grown into nearby areas. Spread to regional lymph nodes (N). Spread (metastasis) (M) to other organs of the body. Once the T, N, and M categories have been determined, this information is combined into a prognostic group. Higher numbers mean the cancer is more advanced. Pathologic staging is based on the operative and pathology report from cystectomy at the local site. Complete pathologic response (pT0) is defined as pT0 N0 M0.
Time frame: 14 weeks of treatment plus cystectomy within 70 days of treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pembrolizumab, Gemcitabine and Cisplatin | Percentage of Subjects That Reach Complete Pathologic Response (pT0) at the Time of Cystectomy | 36 percentage of patients with response |